论文信息 - Efficacy and safety of nivolumab (NIVO) in patients with advanced melanoma (MEL) and poor prognostic factors who progressed on or after ipilimumab (IPI): Results from a phase II study (CheckMate 172). - 字舞流文

Efficacy and safety of nivolumab (NIVO) in patients with advanced melanoma (MEL) and poor prognostic factors who progressed on or after ipilimumab (IPI): Results from a phase II study (CheckMate 172).

D. Schadendorf | P. Ascierto | R. Dummer | A. Carneiro | C. Garbe | H. Gogas | E. Espinosa | G. Hospers | P. Rutkowski | L. Demidov | A. Rorive | J. Haanen | P. Lorigan | T. Guren | P. Nathan | R. Bhore | C. Hoeller | E. Muñoz-Couselo | E. Grigoryeva